Jonathan A. Keller, PharmD, JD; Megan Herber, MPH; Larissa Morgan, JD, MBE

Articles by Jonathan A. Keller, PharmD, JD; Megan Herber, MPH; Larissa Morgan, JD, MBE

DEA’s Proposed Rules on Controlled Substances Prescribing via Telemedicine and Their Uncertain Impact on the Pharmacy Community

ByJonathan A. Keller, PharmD, JD; Megan Herber, MPH; Larissa Morgan, JD, MBE

April 28th 2023

Proposed rules would permit a telehealth provider to prescribe only up to a 30-day supply of a Schedule III-V non-narcotic controlled substance or buprenorphine through telehealth without the patient first being evaluated in person by a provider.

Jonathan A. Keller, PharmD, JD; Megan Herber, MPH; Larissa Morgan, JD, MBE

Articles by Jonathan A. Keller, PharmD, JD; Megan Herber, MPH; Larissa Morgan, JD, MBE

DEA’s Proposed Rules on Controlled Substances Prescribing via Telemedicine and Their Uncertain Impact on the Pharmacy Community

Latest Updated Articles

Trending on Pharmacy Times

Eli Lilly, Novo Nordisk Strike MFN Deals With Trump Administration to Lower GLP-1 Prices

FDA Approves Lumateperone With Antidepressant Use for Major Depressive Disorder

MFN, DTC, and the Policy Pressure Cooker: Reshaping the US Drug Market

Gedatolisib Triplet Shows Significant PFS Benefit in HR+/HER2– Breast Cancer

Population Genomic Screening Improves Lipid Management in Familial Hypercholesterolemia